CS
CSBTF.US Kuros Biosciences AG
- Market cap
- USD 958M
- P/E
- 109.5x
- P/B
- 11.14x
- ROE
- 19.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CSBTF.US undervalued?
Graham numberThe Graham number of Kuros Biosciences AG cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kuros Biosciences AG fundamental analysis
No fundamental analysis for Kuros Biosciences AG yet.
Kuros Biosciences AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or po…
Full company profileKuros Biosciences AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kuros Biosciences AG annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.06M | 534K | 715K | 2.56M | 4.04M | 13.8M | 18.0M | 33.6M | 75.6M | 121M | 289M |
| Gross Profit | -2.89M | -2.77M | -2.70M | -79.0K | 1.67M | 10.1M | 10.8M | 28.5M | 62.0M | 105M | 246M |
| Operating Income | -21.3M | -16.2M | -13.7M | -11.4M | -11.7M | -8.77M | -13.4M | -13.2M | -5.00M | 7.33M | 16.2M |
| EBITDA | -19.3M | -15.1M | -11.7M | -8.46M | -8.58M | -5.29M | -6.92M | -6.65M | -561K | 10.0M | 23.2M |
| Net Income | -19.7M | -16.5M | -11.7M | -11.3M | -11.5M | -7.54M | -14.6M | -13.7M | -3.72M | 2.12M | 13.8M |
| EPS | -3.19 | -1.88 | -1.14 | -0.66 | -0.47 | -0.23 | -0.43 | -0.38 | -0.10 | 0.05 | 0.35 |
| Balance Sheet | |||||||||||
| Total Assets | 43.8M | 86.1M | 85.8M | 87.9M | 94.4M | 91.3M | 82.9M | 71.5M | 84.5M | 107M | 119M |
| Total Liabilities | 5.45M | 12.9M | 9.34M | 10.00M | 9.76M | 14.4M | 14.1M | 14.8M | 25.8M | 49.4M | 47.9M |
| Shareholders' Equity | 38.3M | 73.1M | 76.5M | 77.9M | 84.6M | 77.0M | 68.9M | 56.7M | 58.7M | 67.0M | 71.6M |
| Cash & Short-term Investments | 12.4M | 16.7M | 18.3M | 20.8M | 28.4M | 28.6M | 24.1M | 14.2M | 17.5M | 15.7M | 7.81M |
| Total Debt | - | - | - | 2.39M | 2.34M | 2.15M | 1.91M | 2.14M | 1.79M | 1.39M | 10.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.89M | -10.7M | -12.8M | -10.8M | -9.24M | -5.45M | -7.35M | -8.84M | 3.14M | -378K | -8.90M |
| Capital Expenditure | 50.0K | 1.57M | 662K | 118K | 220K | 374K | 400K | 326K | 1.11M | 2.03M | 21.0M |
| Free Cash Flow | -8.94M | -12.3M | -13.5M | -11.0M | -9.46M | -5.83M | -7.75M | -9.17M | 2.03M | -2.40M | -29.9M |
| Ratios | |||||||||||
| ROE | -51.5% | -22.5% | -15.3% | -14.5% | -13.6% | -9.8% | -21.2% | -24.2% | -6.3% | 3.2% | 19.3% |
| ROA | -45.1% | -19.1% | -13.6% | -12.8% | -12.2% | -8.3% | -17.6% | -19.2% | -4.4% | 2.0% | 11.5% |
| Net Profit Margin | -1,860.9% | -3,086.9% | -1,635.4% | -439.4% | -285.2% | -54.6% | -81.1% | -40.9% | -4.9% | 1.7% | 4.8% |
| Debt to Equity | - | - | - | 0.03x | 0.03x | 0.03x | 0.03x | 0.04x | 0.03x | 0.02x | 0.15x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kuros Biosciences AG dividends
Kuros Biosciences AG has not paid dividends in the last 9 fiscal years.
Last stock split: 1:100 on Jun 23, 2016.
Who owns Kuros Biosciences AG
- Insiders 33.80%
- Institutions 23.54%
- Public & others 42.66%
- Shares outstanding 39.8M
- Free float 30.6M
Kuros Biosciences AG company profile
- Company name
- Kuros Biosciences AG
- Ticker
- CSBTF.US
- ISIN
- CH0325814116
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 213
- Fiscal year end
- December
- Address
- Wagistrasse 25, Schlieren, Switzerland, 8952
- Phone
- 41 44 733 4747
- Website
- kurosbio.com
About Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
Kuros Biosciences AG management
10- Mr. Christopher T. Fair B.B.A.CEO & Director · born 1970
- Mr. Daniel GeigerChief Financial Officer · born 1971
- Dr. Joost D. de Bruijn B.Sc. Ph.D., Ph.D.President of Innovation and Strategy & Executive Director · born 1966
- Mr. Harry Thomas HallChief Operating Officer
- Mr. G. Joseph RossSenior Vice President of Marketing & Business Development · born 1968
- Ms. Laura RosaSenior Vice President of Global Human Resources
- Dr. Philippe Saudan Ph.D.Senior Vice President of Quality, Regulatory & Clinical · born 1967
- Mr. John GriffinChief Business Officer
- Ms. Carly DummerSenior Director of Marketing
- Dr. Virginia JamiesonConsultant · born 1953